Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Breast Neoplasms 17Carcinoma, Renal Cell 14Neoplasms 12Neoplasm Metastasis 9Neuroendocrine Tumors 7Head and Neck Neoplasms 7Kidney Neoplasms 6Pancreatic Neoplasms 5Prostatic Neoplasms 4Lung Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Recurrence 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma 3Leukemia, Lymphocytic, Chronic, B-Cell 3Carcinoma, Non-Small-Cell Lung 3Carcinoma, Hepatocellular 3Waldenstrom Macroglobulinemia 2Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Somatostatinoma 2Pheochromocytoma 2Paraganglioma 2Neuroectodermal Tumors, Primitive 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, Follicular 2Insulinoma 2Hodgkin Disease 2

Interventions

rofecoxib 1rindopepimut 1imetelstat 1GRN163L peptide 1Everolimus 1Dasatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Brain Stem Neoplasms × Everolimus × Clear all
NCT03352427 2022-10-05

Study of Dasatinib in Combination With Everolimus for Children and Young Adults With Gliomas Harboring Platelet-Derived Growth Factor Receptor (PDGFR) Alterations

University of Michigan Rogel Cancer Center

Phase 2 Terminated
3 enrolled 7 charts
CNS

Glioma, Brain Stem Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡